The latest announcement is out from Glaukos ( (GKOS) ).
Glaukos Corporation’s innovative iDose TR therapy is set to revolutionize glaucoma treatment with its long-duration drug delivery system, offering relief for up to three years. The company has invested over $600 million in research and development, studying 1,150 subjects in Phase 3 trials, and successfully achieving FDA approval. Designed to address high rates of non-compliance with traditional topical medications, iDose TR promises continuous, reliable treatment for glaucoma patients, significantly improving their quality of life.
See more insights into GKOS stock on TipRanks’ Stock Analysis page.
